Bioscience Company Reports Positive FDA Meeting For Severe Pain Treatment

Ensysce Biosciences: A Leap Forward in Severe Pain Treatment with PF614.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In an exciting development for the medical community and patients suffering from severe pain, Ensysce Biosciences Inc. (NASDAQ: ENSC) has announced a positive end-of-Phase-2 meeting with the U.S. Food and Drug…